Epizyme, Inc. to Present at Upcoming Conferences in February

RBC Capital Markets Global Healthcare Conference 2015
Leerink Global Healthcare Conference 2015

CAMBRIDGE, Mass.--()--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences in February:

  • 2015 Leerink Global Healthcare Conference at the Waldorf Astoria in New York on Thursday, February 12 at 2:15 p.m. EST.
  • SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day at the JW Essex House in New York on Monday, February 23. Company management will participate in 1x1 meetings.
  • RBC Capital Markets 2015 Global Healthcare Conference at the New York Palace Hotel in New York on Tuesday, February 24 at 10:30 a.m. EST.

Live webcasts for the Leerink and RBC Capital Markets events will be available by visiting the Investor Center of the Epizyme website at www.epizyme.com. Archived replays of the webcasts will be available on the Company’s website for 30 days after the conference.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Contacts

Epizyme, Inc.
Media/Investors:
Manisha Pai, 617-229-7560
mpai@epizyme.com

Epizyme, Inc.